Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 4/20 | 0.68 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | CTSC | P53634 | 1/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.53 |
| ▸ | GNPAT | O15228 | 1/20 | 0.53 |
| ▸ | CPA3 | P15088 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048911 | 1.00 | NAALAD2 (0.68) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL6236774 | 1.00 | NAALAD2 (0.68) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL6237394 | 0.97 | NAALAD2 (0.64) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL27652943 | 0.97 | NAALAD2 (0.64) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL30692726 | 0.96 | NAALAD2 (0.67) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL30849218 | 0.95 | NAALAD2 (0.61) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL30123529 | 0.94 | NAALAD2 (0.60) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL22649263 | 0.94 | NAALAD2 (0.60) | NAALAD2SLC15A1POLBLTA4HCTSC | |
| SCHEMBL29892222 | 0.93 | NAALAD2 (0.67) | NAALAD2SLC15A1POLBLTA4HGNPAT | |
| SCHEMBL30688832 | 0.93 | NAALAD2 (0.67) | NAALAD2SLC15A1POLBLTA4HGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1930183-B | Bioactive peptides comprising phenylalanyl-glutamic acid and phenylalanyl-glutamyl-glutamic acid | PEPHARM R & D LTD | 2010-12-29 | — | — | CN | claimed |
| CN-1930183-A | Bioactive peptides comprising phenylalanyl-glutamic acid and phenylalanyl-glutamyl-glutamic acid | PEPHARM R & D LTD (CN) | 2007-03-14 | — | — | CN | claimed |
| WO-2005016959-A1 | BIOLOGICALLY ACTIVE PEPTIDES COMPRISING PHENYLALANYL-GLUTAMATE (FE) AND PHENYLALANYL-GLUTAMYL-GLUTAMATE (FEE) | PEPHARM R & D LIMITED (CN) | 2005-02-24 | — | — | WO | claimed |
| CN-1930183-B | Bioactive peptides comprising phenylalanyl-glutamic acid and phenylalanyl-glutamyl-glutamic acid | PEPHARM R & D LTD | 2010-12-29 | — | — | CN | disclosed |
| US-20100158905-A1 | COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| CN-1930183-A | Bioactive peptides comprising phenylalanyl-glutamic acid and phenylalanyl-glutamyl-glutamic acid | PEPHARM R & D LTD (CN) | 2007-03-14 | — | — | CN | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158905-A1 | COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST | PTGS2, PTGES2, PTGES | NAALAD2 180/4885SLC15A1 2976/4885POLB 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.